In this study, we identified TAOK1 as a potential therapeutic target in ESCC, and Deferasirox, an FDA-approved iron chelator, exerted significant antitumor effects by inhibiting TAOK1 independent of its iron-chelating function. This evidence concerns the gene TAOK1 and esophageal squamous cell carcinoma.